Below is a roundup of fitness news.
The combination of Imfinzi and AstraZeneca chemoradiation fails the number one endpoint of the late-stage trial
Drugmaker AstraZeneca said on Tuesday that its cancer drug Imfinzi, given in combination with chemoradiation therapy (CRT), failed to meet its number one endpoint in a late-stage trial to treat unresectable level 3 mobile lung cancer. Imfinzi administered sequentially after platinum-based CRT is already an established popular treatment for the treatment of this type of lung cancer.
Novo Nordisk Shares Rise as Wegovy Shows Heart Benefits Beyond Weight Loss
Novo Nordisk shares jumped 3% on Monday as the market reacted to information presented through the drugmaker over the weekend, according to which the center’s coverage benefits from its popular anti-obesity drug, Wegovy, solely because of weight loss. Data presented Saturday at a primary medical assembly in the United States gave investors and analysts even more confidence in Wegovy’s core earnings after Novo released initial data from its first study in August, sending its shares soaring 17% that day to an all-time high.
Belgium bans the use of Ozempic for weight loss until the summer
Belgium has taken the decision to temporarily ban the use of Novo Nordisk’s diabetes drug Ozempic as a weight-loss remedy due to shortages of the drug, according to a royal decree published in the country’s Official Gazette on Tuesday. Ozempic is approved to treat type 2 diabetes, yet it is increasingly being prescribed “off-label” to treat weight loss because it comprises the same active element as Novo’s hugely popular (and rare) anti-obesity drug, Wegovy.
Healthcare Executives Expect M&A Activity to Return in 2024, Survey Finds
Merger and acquisition (M&A) activity in the global healthcare sector is expected to continue increasing next year, driven by healthcare corporations rather than personal capital, according to a survey of industry executives. The report, released Tuesday through investment bank Jefferies, surveyed six hundred senior industry executives. The study found that 68% of respondents expect healthcare deal volume to increase in 2024, with 60% of healthcare companies dominating deals.
Seriously ill British woman dies after her life was taken – family
Indi Gregory, a seriously ill eight-month-old British girl who was kicked out of intensive care over the weekend following a legal war, died overnight, her circle of relatives said on Monday. Gregory’s parents lost a legal battle last month over keeping her alive and moving her to a Vatican children’s hospital in Rome.
Adding Chickenpox Vaccine to UK Formative Years Immunisation Programme: Vaccine Advisors
Britain deserves to include the chickenpox vaccine in its formative years immunization programme, the government’s vaccine advice framework said on Tuesday. This advice would bring the UK closer to many other countries, such as the United States and Germany, which vaccinate young people who are opposed to the disease. .
Catalent Delays $700 Million Quarterly Impairment Charge to SEC
Catalent will delay its quarterly filing with the U. S. securities regulator. The company said the company was moving to the U. S. due to a goodwill impairment rate of about $700 million, similar to acquisitions in the company’s biomodalities and customer fitness unit, the company said. Corporate Monday night. The contract drugmaker, whose annual effects have been delayed several times this year due to production problems, said it would report initial first-quarter effects on Wednesday.
Pfizer to cut 500 UK jobs as part of wider pay cuts
Pfizer will cut 500 jobs at its Sandwich in Kent, UK, as part of its $3. 5 billion cost-cutting plan, the drugmaker said on Tuesday. The U. S. drugmaker announced a cost-cutting program in October after lowering its full-year profit forecast due to lower-than-expected sales of its COVID-19 vaccine and treatment.
European regulator backs GSK’s bone marrow treatment
British drugmaker GSK said on Monday that the European Medicines Agency’s Committee for Medicinal Products for Human Use had advised approval of its oral remedy to treat anaemia in patients with a type of bone marrow cancer called myelofibrosis. momelotinib, is expected until early 2024, GSK said in a statement.
(With agencies. )